comscoreWhere Are We With Immunotherapy to Treat Breast Cancer? -- Heard in the Halls: Voices From the 2017 San Antonio Breast Cancer Symposium

Where Are We With Immunotherapy to Treat Breast Cancer? -- Heard in the Halls: Voices From the 2017 San Antonio Breast Cancer Symposium

Leisha Emens, MD, PhD, discusses the state of immunotherapy to treat breast cancer.
Dec 21, 2017
00:00
Download
00:00

Dr. Leisha Emens discusses the state of immunotherapy to treat breast cancer.

About the guest
 
Leisha Emens headshot
Leisha Emens, MD, PhD

Dr. Leisha Emens is a professor of medicine in hematology/oncology at the University of Pittsburgh Medical Center Hillman Cancer Center. She is also co-leader of the Hillman Cancer Immunology and Immunotherapy Program, and director of translational immunotherapy for the Women's Cancer Research Center. Dr. Emens specializes in cancer immunotherapy, and her research focuses on the development and implementation of breast cancer immunotherapies (including vaccines and immune checkpoint inhibitors) in combination with traditional cancer treatments and other drugs that activate the immune system. Dr. Emens discloses that she has received research support from Merck, EMD-Serono, AstraZeneca, Genentech-Roche, Corvus, and Aduro. She has received honoraria from Vaccinex, Amgen, Syndax, Peregrine, Bayer, and Gritstone.

— Last updated on June 29, 2022, 2:48 PM

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate